AnaptysBio - Home
About
Overview
Strategy
Management
Board of Directors
Therapeutic Advisory Board
Technology
Therapeutic Antibodies
Somatic Hypermutation
SHM Platform
Key Advantages
Publications
Pipeline
Overview
ANB020
ANB019
Checkpoint Agonists
Partnerships
Investors / News
Overview
News
Events
Goverance
Stock Information
Analyst Coverage
SEC Filings
FAQs
Contact
Careers
Overview
Job Openings
Health and Financial Benefits Overview
Contact
Toggle
Therapeutic Antibodies
for Severe Disease
Therapeutic Antibodies
for Severe Disease
Therapeutic Antibodies
for Severe Disease
March 26, 2018
AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients
AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients
February 17, 2018
AnaptysBio Presents Updated Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting
AnaptysBio Presents Updated Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting
About
Technology
Pipeline
Investors
Careers
